多发性硬化患者血清和脑脊液中S-100b蛋白测定及临床意义

Clinical Significance of the Level of S-100b Protein in Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis

为探讨S 10 0b蛋白与多发性硬化 (MS )临床的关系 ,采用ELISA方法检测 6 0例急性活动期MS ,2 6例对照组血清及脑脊液中S 10 0b含量 ,并进行比较分析。结果发现 ,血清及脑脊液中S 10 0b水平 ,急性活动期MS高于对照组 (P均 <0 0 1) ,MS组血清和脑脊液中S 10 0b含量异常增高者分别为 2 0 %和 96 6 % ;脑脊液S 10 0b水平MS急性活动 7d内高于急性活动 7d以上者 (P <0 0 5 ) ,两者又均高于对照组 (P均 <0 0 1) ;血清S 10 0b水平MS急性活动 7d内高于急性活动 7d以上者及对照组 (P均 <0 0 1) ,急性活动 7d后与对照组比较无差异 (P >0 0 5 ) ;脑脊液S 10 0b水平不同病残程度之间比较无显著性差异 (P >0 0 5 ) ,血清S 10 0b水平在中、重度病残者高于轻度病残者 (P均 <0 0 1) ,重度病残者虽高于中度病残者 ,但差异无显著性意义 (P >0 0 5 )。提示S 10 0b蛋白可作为判断MS疾病活动性及病情严重程度的重要生化标志物之一。

To investigate the relationship between the S-100b protein and multiple sclerosis (MS),the level of this protein was determined in sera and cerebrospinal fluid (CSF) of 60 patients with MS and 26 cases of control by means of ELISA. The results showed that the level of the S-100b protein in sera and CSF in active cases of MS was significantly higher than that of the control group,with an abnormally high levels of S-100b protein in sera and CSF of 20% and 96.6% respectively. The level of S-100b protein in CSF of active MS within 7 days was higher than those cases of active MS over 7 days and the controls,with no significant difference in these latter two groups,and the level of the S-100b protein in CSF of acute and active MS showed no significant difference with the degree of disability. But the level of S-100b protein in sera of cases with severe disability was higher than those of cases with mild disability,although the cases with severe disability showed a higher level of S-100b protein than those cases with moderate disability,yet the difference did not reach statistical significance. It concludes that the level of the S-100b protein may be used as an important biochemical marker to judge the activity and severity of multiple sclerosis.